SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Cash from Investing (Quarterly): 21.46M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.46M |
| December 31, 2023 | -159.20M |
| September 30, 2023 | 34.60M |
| June 30, 2023 | 60.76M |
| March 31, 2023 | 98.60M |
| December 31, 2022 | -355.01M |
| September 30, 2022 | 86.23M |
| June 30, 2022 | 26.76M |
| March 31, 2022 | 26.42M |
| December 31, 2021 | 56.18M |
| September 30, 2021 | 35.78M |
| Date | Value |
|---|---|
| June 30, 2021 | 22.54M |
| March 31, 2021 | -30.92M |
| December 31, 2020 | -222.78M |
| September 30, 2020 | -127.56M |
| June 30, 2020 | -68.33M |
| March 31, 2020 | -0.16M |
| December 31, 2019 | -0.13M |
| September 30, 2019 | -0.084M |
| June 30, 2019 | -3.785M |
| March 31, 2019 | -0.261M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-355.01M
Minimum
Dec 2022
98.60M
Maximum
Mar 2023
-24.93M
Average
10.69M
Median
Cash from Investing (Quarterly) Benchmarks
| Geron Corp | 34.21M |
| Verastem Inc | 30.98M |
| Karyopharm Therapeutics Inc | 21.94M |
| Syndax Pharmaceuticals Inc | -99.40M |
| Arvinas Inc | -127.80M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -78.93M |
| Cash from Financing (Quarterly) | -0.552M |
| Free Cash Flow | -244.89M |
| Free Cash Flow Per Share (Quarterly) | -1.078 |
| Free Cash Flow to Equity (Quarterly) | -79.51M |
| Free Cash Flow Yield | -8.27% |